Results of Operations and Financial Condition. On August 11, 2026, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securitie…

Director — Tim Walbert: Mr. Walbert resigned due to other commitments.

Compensatory arrangements and equity grants to existing officers.

(including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Entry into a Material Definitive Agreement. On April 27, 2026, Sagimet Biosciences Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with Leerink Partners LLC, TD Securities (USA) LLC, and Guggenheim Securities, LLC as representatives of the several underwriters named therein (the “ Underwriters ”) relating to an underwritten offering (the “ Offering ”) of 29,166,700 shares (the “ Shares ”) of the Company’s Series A common stock, par value $0.0001…

Results of Operations and Financial Condition. Sagimet Biosciences, Inc. (the “ Company ”) is furnishing with this Current Report on Form 8-K (the “Current Report”) certain unaudited preliminary financial information for the Company’s fiscal quarter ended March 31, 2026. Certain Unaudited Preliminary Financial Information The Company estimates that its cash, cash equivalents and marketable securities were approximately $104.5 million as of March 31, 2026. This amount is unaudited and prelimin…

Chief Medical Officer — Eduardo Martins, M.D., D.Phil.: Dr. Eduardo Martins retired from his role as Chief Medical Officer but will continue to support the company as an external scientific advisor.

Results of Operations and Financial Condition On March 11, 2026, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2025. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18…

Results of Operations and Financial Condition On November 13, 2025, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Sec…

Changes in Registrant’s Certifying Accountant. On August 18, 2025, the Audit Committee of the Board of Directors (the “Board”) of Sagimet Biosciences Inc. (the “Company”) recommended and the Board approved (i) the appointment of KPMG LLP (“KPMG”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 and related interim periods and, concurrently, (ii) the dismissal of Deloitte & Touche LLP (“Deloitte”) as the Company’s independent registere…

Results of Operations and Financial Condition On August 13, 2025, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities…

Amended executive employment agreements were entered into, modifying severance provisions.

Results of Operations and Financial Condition On May 8, 2025, Sagimet Biosciences Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities…

Director — Merdad Parsey, M.D., Ph.D.: Dr. Parsey will not stand for re-election at the Company’s 2025 Annual Meeting of Stockholders.

(including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Results of Operations and Financial Condition On November 14, 2024, Sagimet Biosciences Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended September 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the S…

Results of Operations and Financial Condition On August 14, 2024, Sagimet Biosciences Inc. (the “ Company ”) issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securiti…

Director — Jennifer Jarrett and Dr. Anne Phillips: The board expanded from seven to nine directors, appointing Jennifer Jarrett and Dr. Anne Phillips as new Class III directors.

Results of Operations and Financial Condition On May 15, 2024, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02 (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities E…

Chief Financial Officer — Thierry Chauche: Mr. Chauche was appointed as the Chief Financial Officer, replacing the interim Principal Financial Officer.

Director — Tim Walbert: The board expanded and appointed Tim Walbert as a new director.

Results of Operations and Financial Condition On March 25, 2024, Sagimet Biosciences Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Chief Financial Officer — Anthony Rimac: The CFO resigned, and an interim officer was appointed.

Results of Operations and Financial Condition. On January 23, 2024, Sagimet Biosciences Inc. (the “Company”) announced that it estimates that its cash, cash equivalents and short-term investments in marketable securities were approximately $94.9 million as of December 31, 2023. This unaudited, preliminary amount has been prepared by and is the responsibility of management. This amount is based upon information available to management as of the date of this Current Report on Form 8-K and subje…

Chief Financial Officer — Anthony Rimac: Mr. Rimac resigned for personal reasons.